TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: A Study To Evaluate The Efficacy And Safety Of TNX-102 SL In Patients With Fibromyalgia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* The patient is male or female 18 to 65 years of age, inclusive.~* The patient has a diagnosis of primary FM as defined by the 2016 Revisions to the 2010/2011 fibromyalgia diagnostic criteria (American College of Rheumatology Preliminary Diagnostic Criteria)~* The in-clinic 7-day recall NRS average daily pain intensity score at Screening Visit within protocol specified range.~Exclusion Criteria:~* History of or evidence for a diagnosis of borderline personality disorder (BPD).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- TNX-102 SL Tablets, 5.6 mg (Type: EXPERIMENTAL): 1 x TNX-102 SL 2.8 mg Tablet taken sublingually each day at bedtime for 2 weeks then 2 x TNX-102 SL 2.8 mg (5.6 mg) Tablet taken sublingually each day at bedtime for 12 weeks.
- Placebo SL Tablet (Type: PLACEBO_COMPARATOR): 1 x Placebo Tablet taken sublingually each day at bedtime for 2 weeks then 2 x Placebo Tablet taken sublingually each day at bedtime for 12 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Medtronic Concomitant Utilization of Radio Frequency for Atrial Fibrillation CURE-AF/Persistent

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. Patients must have a documented history of persistent AF as defined by the ACC/AHA/ESC Guidelines: Characterized as episodes of non-self-terminating atrial fibrillation that usually lasts more than 7 days.~2. Concomitant indication (other than AF) for open-heart surgery for one or more of the following:~   * Mitral valve repair or replacement~  * Aortic valve repair or replacement~  * Tricuspid valve repair or replacement~  * Atrial septal defect (ASD) repair~  * Patent foramen ovale (PFO) closure~  * Coronary artery bypass procedures~3. Greater than or equal to 18 years of age~4. Able and willing to comply with study requirements by signing a consent form~5. Must be able to take the anticoagulant warfarin (Coumadin)~Exclusion Criteria:~1. Wolff-Parkinson-White syndrome~2. NYHA Class = IV~3. Left ventricular ejection fraction ≤ 30%~4. Need for emergent cardiac surgery (i.e. cardiogenic shock)~5. Previous atrial ablation for AF, AV-nodal ablation, or surgical Maze procedure~6. Contraindication for anticoagulation therapy~7. Left atrial diameter \> 7.0 cm~8. Preoperative need for an intra-aortic balloon pump or intravenous inotropes~9. Renal failure requiring dialysis or hepatic failure~10. Life expectancy of less than one year~11. Pregnancy or desire to be pregnant within 12 months of the study treatment.~12. Current diagnosis of active systemic infection~13. Documented MI 6 weeks prior to study enrollment

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Radiofrequency Neurotomy In Relieving Chronic Knee Pain

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* chronic arthritis according to the American College of Rheumatology criteria~* diagnosed radiologically patients in stage 3 and 4, according to the Kellgren-Lawrence classification~Exclusion Criteria:~* other causes of pain such as radiculopathy, neurological disorders, or intermittent claudication.~* patients receive intraarticular steroid or hyaluronic acids during previous three months.~* patients did previous knee surgery.~* Patients with general contraindication to the application of invasive intervention such as hemorrhage, coagulation disorder, systemic infection or local infection.~* patients with other connective tissue disease affecting the knee. And 6-psychiatric disorders.

- Gender: ALL
- Minimum Age: 30 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- radiofrequency group (Type: ACTIVE_COMPARATOR): radiofrequency was done in the three genicular nerves upper medial and upper lateral and lower medial
- conventional group (Type: ACTIVE_COMPARATOR): the patients received conventional paracetamol and non steroidal antiinflammatory

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Global Study to Assess the Effects of MEDI4736 (Durvalumab), Given as Monotherapy or in Combination With Tremelimumab Determined by PD-L1 Expression Versus Standard of Care in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~* Aged at least 18 years~* Documented evidence of NSCLC (Stage IIIB/ IV disease)~* Disease progression or recurrence after both a platinum-based chemotherapy regimen and at least 1 additional regimen for treatment of NSCLC~* World Health Organization (WHO) Performance Status of 0 or 1~* Estimated life expectancy more than 12 weeks~Exclusion Criteria:~* Prior exposure to any anti-PD-1 or anti-PD-L1 antibody or anti-CTLA4~* Brain metastases or spinal cord compression unless asymptomatic, treated and stable (not requiring steroids)~* Active or prior documented autoimmune disease within the past 2 years~* Evidence of severe or uncontrolled systemic disease, including active bleeding diatheses or active infections including hepatitis B, C and HIV~* Any unresolved toxicity CTCAE (Common Terminology Criteria of Adverse Events) \>Grade 2 from previous anti-cancer therapy~* Known EGFR TK activating mutations or ALK rearrangements~* Any prior Grade ≥3 immune-related adverse event (irAE) while receiving any previous immunotherapy agent, or any unresolved irAE \>Grade 1~* Active or prior documented inflammatory bowel disease (eg, Crohn's disease, ulcerative colitis)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 130 Years
- Healthy Volunteers: f

Study Arms:
- MEDI4736 (durvalumab) monotherapy in Sub-study A (Type: EXPERIMENTAL): MEDI4736 (durvalumab) by intravenous infusion. Sub-study A for patients with PD-L1 positive tumors.
- Standard of Care in Sub-study A (Type: ACTIVE_COMPARATOR): Investigator choice from Vinorelbine, Gemcitabine and Erlotinib. Sub-study A for patients with PD-L1 positive tumors.
- MEDI4736 (durvalumab) + tremelimumab in Sub-study B (Type: EXPERIMENTAL): MEDI4736 (durvalumab) by intravenous infusion and tremelimumab by intravenous infusion. Sub-study B for patients with PD-L1 negative tumors.
- Standard of Care in Sub-study B (Type: ACTIVE_COMPARATOR): Investigator choice from Vinorelbine, Gemcitabine and Erlotinib. Sub-study B for patients with PD-L1 negative tumors.
- MEDI4736 (durvalumab) monotherapy in Sub-study B (Type: EXPERIMENTAL): MEDI4736 (durvalumab) by intravenous infusion. Sub-study B for patients with PD-L1 negative tumors.
- tremelimumab in Sub-study B (Type: EXPERIMENTAL): tremelimumab by intravenous infusion. Sub-study B for patients with PD-L1 negative tumors.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of Trifluridine/Tipiracil (TAS-102) in Patients With Metastatic Colorectal Cancer in Asia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Has provided written informed consent~* Has adenocarcinoma of the colon or rectum~* Has failed at least 2 prior regimens of standard chemotherapies for metastatic colorectal cancer~* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1~* Is able to take medication orally~* Has adequate organ function (bone marrow, kidney and liver)~* Women of childbearing potential must have a negative pregnancy test and must agree to adequate birth control if conception is possible. Males must agree to adequate birth control.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- TAS-102 (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Dose Study in Healthy Japanese Males Investigating Safety, Pharmacokinetics and Pharmacodynamics of NNC126-0083

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy male subjects with Japanese passport and Japanese born parents~* Body Mass Index (BMI, kg/m2) between 18.0 and 27.0, both inclusive~* Subjects must be in good health according to age~Exclusion Criteria:~* A history or presence of cancer, diabetes, or any clinically significant cardiovascular, respiratory, metabolic, renal, hepatic, gastrointestinal, endocrinological, haematological, dermatological, venereal, neurological, psychiatric diseases or other major diseases~* History of any illnesses or disease that, in the opinion of the Investigator might confound the results of the trial or pose additional risk in administering the trial product to the subject~* Any clinically significant abnormal haematology, biochemistry or urinalysis screening tests, as judged by the Investigator

- Gender: MALE
- Minimum Age: 20 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- A (Type: EXPERIMENTAL): None
- B (Type: EXPERIMENTAL): None
- C (Type: EXPERIMENTAL): None
- D (Type: EXPERIMENTAL): None
- E (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Dapagliflozin Effect on Symptoms and Biomarkers in Patients With Heart Failure

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Established diagnosis of New York Heart Association (NYHA) Class II or Class III heart failure (left ventricular ejection fraction ≤40% due to either ischemic or non-ischemic etiology) with reduced systolic function for at least 16 weeks prior to enrollment~2. No change in diuretic management for at least 1 week prior to enrollment~3. Brain natriuretic peptide (BNP) ≥100 pg/mL and/or N-terminal pro b-type natriuretic peptide (NTproBNP) ≥ 400 pg/mL at enrollment~Exclusion Criteria:~1. History of type 1 diabetes~2. Estimated glomerular filtration rate (eGFR) \< 30 at enrollment~3. Hospitalization for heart failure within the 30 days prior to enrollment~4. Admission for an acute coronary syndrome (ST-elevation myocardial infarction, non-ST-elevation myocardial infarction, or unstable angina), percutaneous coronary intervention, or cardiac surgery within the 30 days prior to enrollment~5. Admission for cardiac resynchronization therapy (CRT) within 90 days prior to the screening visit~6. Planned cardiovascular revascularization (percutaneous intervention or surgical) or major cardiac surgery (coronary artery bypass grafting, valve replacement, ventricular assist device, cardiac transplantation, or any other surgery requiring thoracotomy) within the 90 days after enrollment~7. Patients who are volume depleted based upon physical examination at the time of screening or randomization

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: 119 Years
- Healthy Volunteers: f

Study Arms:
- Dapagliflozin (Type: ACTIVE_COMPARATOR): Dapagliflozin 10 mg daily
- Dapagliflozin matching placebo (Type: PLACEBO_COMPARATOR): Dapagliflozin matching placebo 10 mg daily

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Methylene Blue for Cognitive Dysfunction in Bipolar Disorder

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Men or women between the ages of 18 and 65 who meet both RDC and DSM-IV criteria for bipolar I or bipolar II disorder will be recruited.~* All subjects will be interviewed using SADS interview (40) with added questions as to arrive at DSM-IV diagnoses as well.~* The patients will be treated with lamotrigine as their main mood stabilizer. Patients recruited for the study will show at least partial response to prophylactic treatment with respect to the mood symptoms.~* HAM-D (17 item) scores at study entry will be 15 or lower and Y MRS scores will be less than 15.~Exclusion Criteria:~* Patients not able to give informed consent~* Patients with active substance abuse or dependence or a history of such within the past two years~* Physical illness, mainly liver and kidney disorders and G-6-PD deficiency~* Subjects previously treated with methylene blue~* Pregnant or breast-feeding women~* Subjects who have had ECT within the past two years~* Patients with known brain injury or loss of consciousness of duration greater than ten minutes~* Subjects taking concurrent medications that are known to have cognitive effects (eg. beta blockers)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Induced and Controlled Dietary Ketosis as a Regulator of Obesity and Metabolic Syndrome Pathologies

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Previously diagnosed with metabolic syndrome~Exclusion Criteria:~* No diagnosis of metabolic syndrome~* \< 18 years old

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Ketogenic group (Type: EXPERIMENTAL): 10-week diet with controlled glycemic indices provided for ketogenic group. Baseline triglyceride, HgA1c, VO2 max, body mass index (BMI), resting metabolic rate (RMR), blood ketone levels and body fat mass measurements were assessed at week 0 and week 3, 6 and 10.
- Exercise group (Type: ACTIVE_COMPARATOR): Exercise group maintained normal diet for 10-weeks and exercised 3-5 days per week. Baseline triglyceride, HgA1c, VO2 max, body mass index (BMI), resting metabolic rate (RMR), blood ketone levels and body fat mass measurements were assessed at week 0 and week 3, 6 and 10.
- Non-exercise (Type: ACTIVE_COMPARATOR): Non-exercise group maintained normal diet for 10-weeks with no exercise. Baseline triglyceride, HgA1c, VO2 max, body mass index (BMI), resting metabolic rate (RMR), blood ketone levels and body fat mass measurements were assessed at week 0 and week 3, 6 and 10.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Prucalopride for Postoperative Ileus in Patients Undergoing Gastrointestinal Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Consecutive patients undergoing elective gastric, small bowel, or partial colonic resection via laparotomy or laparoscopy.~2. Patients with American Society of Anaesthesiologists grading I-III~3. Informed consent available.~Exclusion Criteria:~1. Patients with stoma creation, extensive adhesiolysis, total or subtotal colectomy , or patients who had a history of total or subtotal colectomy.~2. Patients who developed intraoperative problems or complications, or had peritoneal carcinomatosis.~3. Patients who developed serious complications within 24 hours after surgery.~4. Those who received epidural anesthesia or analgesia.~5. Patients who received other prokinetic drugs.~6. Patients who were allergic to prucalopride.~7. Patients with severe comorbidity and/or organ(kidney, liver, and heart) dysfunction~8. Patients had complete bowel obstruction~9. Patients who have participated other clinical trials.~10. Patients who have short bowel(\<200cm small bowel) or history of constipation.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Prucalopride (Type: EXPERIMENTAL): Prucalopride, 2mg, tablet. First given 24 hours after surgery beginning on POD 1,until bowel movements or for a maximum of 7 days of postoperative treatment
- Placebo (Type: PLACEBO_COMPARATOR): Vitamin C, 50mg, tablet

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Assessment of Pain in People With Thalassemia Who Are Treated With Regular Blood Transfusions

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Participating in the Thalassemia Clinical Research Network Assessment of Pain study~* Has a transfusion dependence of at least eight transfusions per year~* Diagnosis of beta thalassemia or E-beta-thalassemia~* Experiences at least mild pain in the 1 month before study entry, as measured by the response to the Brief Pain Inventory (BPI) question #6 from the Assessment of Pain study~Exclusion Criteria:~* Unwillingness or inability to complete the Brief Pain Inventory Short Form (BPI-SF) on a daily basis

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- age 18-29 (Type: None): People age groups 18-29 with transfusion-dependent thalassemia who have reported at least mild degrees of pain during the main Assessment of Pain study.
- age 30+ (Type: None): People age groups 30+ years with transfusion-dependent thalassemia who have reported at least mild degrees of pain during the main Assessment of Pain study.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Trial Evaluating Efficacy and Safety of Prophylactic Administration of Concizumab in Patients With Severe Haemophilia A Without Inhibitors

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria: - Informed consent obtained before any trial-related activities. Trial-related activities are any procedures that are carried out as part of the trial, including activities to determine the suitability for the trial - Male patients aged 18 years or older at the time of signing informed consent, diagnosed with severe haemophilia A (FVIII activity below 1%), based on medical records or results at screening Exclusion Criteria: - Known or suspected hypersensitivity to trial product(s) or related products - Known inherited or acquired bleeding disorder other than haemophilia A - Presence of inhibitors (neutralising antibodies) to Factor VIII (equal to or above 0.6 Bethesda Units) at screening measured by the Nijmegen method

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Concizumab (Type: EXPERIMENTAL): Daily administration of concizumab to both on-demand and prophylaxis patients

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Comparison of the Blood Sugar Lowering Effect and Safety of Two Insulin Treatments in Type 2 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Type 2 diabetes mellitus for more than 6 months~* HbA1c (glycosylated haemoglobin A1c) between 7.5 % and 10.0% at trial initiation (screening)~* BMI (Body Mass Index) less than 40 kg/m2~* Basal insulin treatment for at least 3 months (NPH once or twice daily, insulin glargine or detemir once daily)~* Treatment with one to 3 OADs~Exclusion Criteria:~* Known or suspected allergy to trial products or related products~* Women who are pregnant, are breast-feeding or intend to become pregnant within the next 48 weeks~* Previous participation in any trial including this for the last 6 months~* Use of more than 1 U/kg of basal insulin daily at trial initiation (screening)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Advanced (Type: EXPERIMENTAL): Insulin detemir once daily + oral anti-diabetic drugs (OADs) with addition of meal-time insulin aspart stepwise (1-2-3) at the meals with the largest prandial increments and individually adjusted insulin aspart based mainly on postmeal SMPG (self monitored plasma glucose). The stepwise addition occurred if the treatment target of HbA1c below 7.0% was not reached after 12, 24 and 36 weeks, respectively.
- Basic (Type: ACTIVE_COMPARATOR): Insulin detemir once daily + oral anti-diabetic drugs (OADs) with addition of meal-time insulin aspart stepwise (1-2-3) at the largest meals and individually adjusted insulin aspart based mainly on pre-meal and bedtime SMPG (self monitored plasma glucose). The stepwise addition occurred if the treatment target of HbA1c below 7.0% was not reached after 12, 24 and 36 weeks, respectively.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete